The Effect of Out-of-pocket Costs and Financial Rewards in a Discrete Choice Experiment: an Application to Lifestyle Programs
Overview
Authors
Affiliations
Background: Both out-of-pocket costs and financial rewards can be used to influence health related behavior. However, it is unclear which of these two has a larger effect on health related behavior. The aim of this study was to explore the possible difference in effect size between out-of-pocket costs and financial rewards on the willingness of diabetes mellitus type 2 (DM2) patients to participate in a lifestyle program.
Methods: A discrete choice experiment (DCE) questionnaire was sent to 767 DM2 patients in a geographically defined area (De Leidsche Rijn, Utrecht) in The Netherlands and completed by 206 of them. The questionnaire comprised of 18 choice tasks of which 9 contained a financial reward for lifestyle program completion, while the other 9 included out-of-pocket costs for program participation. In a second version of the questionnaire, the order of out-of-pocket cost and financial reward choice tasks was counterbalanced to reduce bias with respect to the position (first or second) of the two types of choice tasks. Panel-mixed-multinomial-logit models were used for data analysis.
Results: Increasing out-of-pocket costs were associated with a decreasing willingness to participate in a lifestyle program and, contrary to our expectations, increasing financial rewards were also associated with a decreasing willingness to participate in a lifestyle program. In addition, this willingness to participate changed to the same extent for both increasing out-of-pocket costs and increasing financial rewards.
Conclusions: As expected, increasing out-of-pocket costs may prevent people from deciding to participate in a lifestyle program. However, offering a financial reward to persuade people to participate in a lifestyle program, may result in decreasing willingness to participate in a lifestyle program as well.
You W, Yuan Y, Boyle K, Michaud T, Parmeter C, Seidel R Pharmacoecon Open. 2021; 6(2):193-210.
PMID: 34757584 PMC: 8864042. DOI: 10.1007/s41669-021-00310-6.
Sommer J, Dyczmons J, Grobosch S, Gontscharuk V, Vomhof M, Roden M BMJ Open. 2020; 10(9):e036995.
PMID: 32907900 PMC: 7482475. DOI: 10.1136/bmjopen-2020-036995.
Obembe T, Fonn S PLoS One. 2020; 15(5):e0232882.
PMID: 32433652 PMC: 7239385. DOI: 10.1371/journal.pone.0232882.
Benning T, Dellaert B, Arentze T BMC Public Health. 2020; 20(1):411.
PMID: 32228545 PMC: 7106806. DOI: 10.1186/s12889-020-8416-3.
Molema C, Veldwijk J, Wendel-Vos W, Wit A, van de Goor I, Schuit J PLoS One. 2019; 14(7):e0219112.
PMID: 31344135 PMC: 6657823. DOI: 10.1371/journal.pone.0219112.